10x Genomics (TXG) to Release Earnings on Tuesday

10x Genomics (NASDAQ:TXG) is scheduled to be issuing its quarterly earnings data after the market closes on Tuesday, October 29th. Analysts expect the company to announce earnings of ($0.34) per share for the quarter. 10x Genomics has set its FY 2024 guidance at EPS.Investors that wish to listen to the company’s conference call can do so using this link.

10x Genomics (NASDAQ:TXG) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.15. The firm had revenue of $153.10 million for the quarter, compared to the consensus estimate of $150.90 million. 10x Genomics had a negative net margin of 37.90% and a negative return on equity of 28.23%. On average, analysts expect 10x Genomics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

10x Genomics Trading Up 0.1 %

Shares of NASDAQ:TXG opened at $15.49 on Friday. The firm has a 50 day moving average of $20.51 and a 200-day moving average of $21.89. 10x Genomics has a 12 month low of $14.02 and a 12 month high of $57.90. The stock has a market capitalization of $1.85 billion, a PE ratio of -6.95 and a beta of 1.85.

Insider Buying and Selling

In related news, insider Benjamin J. Hindson sold 4,351 shares of the stock in a transaction on Thursday, August 22nd. The stock was sold at an average price of $22.53, for a total value of $98,028.03. Following the transaction, the insider now directly owns 345,704 shares in the company, valued at $7,788,711.12. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, insider Benjamin J. Hindson sold 4,351 shares of the company’s stock in a transaction dated Thursday, August 22nd. The shares were sold at an average price of $22.53, for a total value of $98,028.03. Following the sale, the insider now owns 345,704 shares in the company, valued at $7,788,711.12. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Justin J. Mcanear sold 2,961 shares of the firm’s stock in a transaction dated Thursday, August 22nd. The shares were sold at an average price of $22.53, for a total transaction of $66,711.33. Following the completion of the transaction, the chief financial officer now directly owns 143,242 shares in the company, valued at approximately $3,227,242.26. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 14,061 shares of company stock valued at $316,794. 10.03% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on TXG. Canaccord Genuity Group reduced their price target on shares of 10x Genomics from $32.00 to $20.00 and set a “buy” rating on the stock in a research note on Thursday, October 10th. Leerink Partners assumed coverage on shares of 10x Genomics in a research note on Tuesday, September 3rd. They set an “outperform” rating and a $35.00 target price on the stock. Bank of America dropped their price target on 10x Genomics from $36.00 to $25.00 and set a “neutral” rating for the company in a research note on Thursday, July 18th. JPMorgan Chase & Co. lowered 10x Genomics from an “overweight” rating to a “neutral” rating and reduced their price objective for the stock from $40.00 to $20.00 in a research report on Thursday, July 18th. Finally, Barclays dropped their target price on 10x Genomics from $24.00 to $21.00 and set an “overweight” rating for the company in a research report on Tuesday, October 15th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $30.60.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.